Program
obinutuzumab
Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.
Drug pageObinutuzumab: every studyAll 172 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 325 open or running | phase 4since Jan 24, 2019 | Aug 16, 2007 | Dec 28, 2026phase 2 · NCT04077723 |
| AbbVie | 32 open or running | phase 3since May 20, 2024 | May 19, 2021 | Nov 2026phase 2 · NCT04895436 |
Also a collaborator on its studies: AstraZeneca and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 19, 2021First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT04895436 · 75 planned · United States, Australia, Austria and more
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05105841 · 20 enrolled · Japan
- May 20, 2024Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06428019 · 170 planned · United States, Australia, France and more
- Jul 19, 2026Named obinutuzumabINNProposed as its International Nonproprietary Name in WHO's List 135
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04895436
- Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06428019
TargetBeta
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 3 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Recruiting | Mar 2028 | 170 |
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | Oct 9, 2025 | 20 |
| NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Recruiting | Nov 2026 | 75 |
How it is read
Names in the registry
- “Obinutuzumab”, 35 entries
- “obinutuzumab”, 5 entries
- “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
- “obinutuzumab (RO5072759)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
- Lymphoma, Non-Hodgkin, 6 studies
- Lymphoma, Follicular, 4 studies
- Lupus Nephritis, 3 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.